The Latest Breaking News on Pharma

The U.S. Office of National Drug Control Policy is designating the tranquilizer xylazine when mixed with fentanyl as an emerging threat

A Texas federal judge’s ruling to remove the 23-year-old drug mifepristone from the market not only threatens abortion access in the U.S. — it’s also an appalling sideswipe at the Food and Drug Administration’s authority and expertise.

The speed of which the Covid jab was developed has "unspooled" medical advancements

The fifth circuit court of appeals is considering the future of mifepristone after the supreme court blocked new restrictions

Biden has one week to appeal

The ruling from U.S. District Judge Matthew Kacsmaryk in Amarillo could potentially upend access to medication abortion nationwide.

After more than five years, three trials and countless hours of legal argument, details can finally be revealed of the brazen attempt to import 1.2 tonnes of meth into Western Australia.

The pharmaceutical industry is positioned for considerable growth in the upcoming years, thanks to increased demand, investments in research and development, and the expansion of e-pharmacy channels. Therefore, A-rated pharmaceutical stocks Astellas Pharma (ALPMY), Ono Pharmaceutical (OPHLY), and Santen Pharmaceutical (SNPHY), trading under $15, could be worth owning in April.…

The drug had been fast-tracked for approval under the agency's accelerated approval program, and has been available for more than a decade, despite the drugmaker's failure to prove that it works.